history of chronic obstructive pulmonary disease (COPD), bronchiectasis, bronchitis, cystic fibrosis or pneumonia, interstitial lung disease (ILD), pulmonary tuberculosis, lung cancer and cough caused ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This in-depth analysis shows that the Global Asthma and COPD Drugs Market, valued at ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those taking DPP-4 drugs.

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

Roflumilast is used to reduce COPD exacerbations in patients with severe chronic bronchitis. The US market for the drug was valued at approximately $32 million as of June 2024, according to IQVIA ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...